Given the critical role of NF-κB in mediating androgen-independent phenotypes in prostate cancer [99], it is tempting to speculate that CDK12 may also play a role in prostate cancer progression and therapy resistance by stimulating this factor, although this concept requires further investigation. This evidence concerns the gene CDK12 and Familial prostate cancer.